Abstract
Background: The Persian Registry of Cardiovascular disease/Heart Failure (PROVE/HF) aimed to studied the demographic, clinical, and diagnostic characteristics and treatment of patients hospitalized for heart failure (HF) and to follow them for short- and long-term outcomes. Its pilot phase started in 2015 in Isfahan aiming to evaluate its feasibility to be scaled up at the national level in later stages. This article describes the method and preliminary results of the first year registry. Materials and Methods: Information of hospitalized patients with preserved and low ejection fraction, were gathered. Patients were followed for 1, 6, and 12 months. During follow-up, information of the patients’ current status, medications used during hospitalization, and in case of death, the cause and place were assessed. Result: PROVE/HF enrolled 787 patients in the first year. The mean age of patients was 70.74 ±12.01 years, and 60.7% of them were men. The most frequent risk factors for the development of HF in the recruited patients was ischemic heart disease (77.9%), and hypertension (63.7%), respectively. The re-admission rate for patients with HF was at least once in 16% and continued until the fifth to ninth re-admission over a one-year period. Among 787 registered patients, 30.9% died in the first year of follow-up, and the in-hospital mortality was 6.2%. The mean hospitalization period was 4.88 days, and 64.2% were hospitalized for >3 days. Conclusion: The annual rate of re-admission and mortality was high, and the use of medication was less than the recommended one inaccordance with the guidelines for the treatment of heart failure. [GMJ.2018;7:e1026]
Highlights
Several cross-sectional and cohort studies in Isfahan have warned the Iranian population about the prevalence of cardiovascular diseases and its risk factors [4-5]
The Persian Registry of Cardiovascular Disease/Heart Failure (PROVE/heart failure (HF)) program, as a pilot study in Isfahan and for the first time in Iran, recorded data of patients admitted with HF and followed them
Questionnaires, protocol, and dictionary were approved by quality control (QC) of PROVE Committee.based on the prepared questionnaire, protocol, and dictionary, data entry was taught to the personnel
Summary
Agradual decrease in mortality rates, in line with increased life expectancy, has increased the elderly population of the world [1]. The age pyramid of Iranian population is changing from youth to elderly [2]. Age increase leads to the decreased health of the cardiovascular system [3]. Several cross-sectional and cohort studies in Isfahan have warned the Iranian population about the prevalence of cardiovascular diseases and its risk factors [4-5]. Cardiovascular mortality has decreased following new therapies [11], which increases the proportion of patients with HF. The Persian Registry of Cardiovascular Disease/Heart Failure (PROVE/HF) program, as a pilot study in Isfahan and for the first time in Iran, recorded data of patients admitted with HF and followed them. Why so comprehensive information of clinical management and epidemiology of HF are not available in the Asian region that makes it hard to compare these issues with Western countries [18]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
